News | September 04, 2008

Dutch Medical Isotopes Unavailable Until End of October

September 4, 2008 - Cancer patients in Europe, and possibly worldwide, may face a longer wait for diagnostic tests and treatments as a nuclear reactor in the Netherlands that supplies medical isotopes extended its shutdown for potential safety reasons.

Nuclear Research and Consultancy Group, which operates the reactor in Petten, in northwestern Netherlands, said Wednesday it would not start up the reactor again before the end of October.

About 15 to 20 percent of Canada's medical isotopes come from overseas, including the Petten facility, according to Health Canada.

"The consequences of this further delay will have an impact on the medical isotope market," the Dutch company said in a statement.

"NRG will not produce any medical isotopes in the months September and October (until 25th of October). We have already informed our customers about the situation. We are assisting in the search for alternative supply routes."

NRG stopped activity at the reactor after air bubbles were discovered in its cooling system. The company has said there is no danger to the public or the environment.

The reactor is the second-biggest producer of medical isotopes worldwide after Atomic Energy of Canada Ltd.'s facility at Chalk River, ON. The Dutch reactor produces the majority of the world supply of isotopes of the element technetium, which give off radiation used in medical imaging and disease treatments.

Technetium-99m is used in 80 percent of diagnostic imaging that uses nuclear medicine technology, including imaging of the heart, kidney and brain. NRG-made isotopes account for seven million diagnostic tests per year in Europe and eight million per year in the U.S., according to the company.

Last week, AECL said that, given the problems in the Netherlands, the nuclear reactor at Chalk River, ON, could ramp up to meet Canada's demand for medical isotopes if required.

But MDS Nordion, a Canadian company that buys isotopes from AECL and sells them to pharmaceutical manufacturers, said: "MDS Nordion does not determine the allocation of medical isotopes to specific end users," such as hospitals in Canada or worldwide.

"We are concerned there is currently no reliable, long-term isotope supply solution to meet this growing demand. As a result, there is risk of isotope shortages recurring," MDS Nordion said in a statement last week.

In December 2007, unexpected problems during routine maintenance at Chalk River forced the reactor to be taken offline, causing a shortage of medical isotopes worldwide.

Source: cbcnews.ca
For more information: www.cbc.ca

Related Content

Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive dec
Male Triathletes May Be Putting Their Heart Health at Risk
News | Cardiac Imaging | January 09, 2018
Competitive male triathletes face a higher risk of a potentially harmful heart condition called myocardial fibrosis,...
Videos | Magnetic Resonance Imaging (MRI) | December 19, 2017
Emanuel Kanal, M.D., director of MRI services and professor of radiology and neuroradiology at the University of Pitt
The FDA issued new warnings on MRI gadolinium contrast agents. (GBCAs)

The FDA issued new warnings on MRI gadolinium contrast agents. 

Feature | Magnetic Resonance Imaging (MRI) | December 19, 2017
The U.S.
Brainlab Contrast Clearance Analysis Software Receives FDA 510(k) Clearance
Technology | Contrast Media | December 12, 2017
Brainlab announced U.S. Food and Drug Administration (FDA) clearance of its Contrast Clearance Analysis methodology,...
Sectra Offers Gadolinium Tracking Functionality in DoseTrack Software
Technology | Contrast Media | December 11, 2017
December 11, 2017 — Sectra recently announced the global introduction of gadolinium tracking in its dose monitoring s
Videos | Magnetic Resonance Imaging (MRI) | December 07, 2017
Max Wintermark, M.D., professor of radiology and chief of neuroradiology, Stanford Hospital and Clinics, discussed MR
Guerbet to Participate in French Interventional Radiology Conference
News | Contrast Media | October 10, 2017
Guerbet announced it will be taking part in the 65th edition of the Journées Francophones de Radiologie (JFR) that will...
Trends in contrast media used in magnetic resonance imaging and computed tomography

Image courtesy of Bayer

Feature | Contrast Media | October 04, 2017 | By Dave Fornell
Over the past decade, several clinical studies have shown gadolinium-based magnetic resonance imaging (MRI) contrast...
Overlay Init